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PLATELETS AND THROMBOPOIESIS
CLEC-2 activates Syk through dimerization
Craig E. Hughes,1 Alice Y. Pollitt,1 Jun Mori,1 Johannes A. Eble,2 Michael G. Tomlinson,3 John H. Hartwig,4
Christopher A. O’Callaghan,5 Klaus Fu¨tterer,3 and Steve P. Watson1
1Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United
Kingdom; 2Centre for Molecular Medicine, Excellence Cluster Cardio-Pulmonary System, Frankfurt University Hospital, Frankfurt am Main, Germany; 3Division
of Hematology, Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, Boston, MA; 4School of Biosciences, College of Life and
Environmental Sciences, University of Birmingham, Birmingham, United Kingdom; and 5Nuffield Department of Clinical Medicine, University of Oxford, Oxford,
United Kingdom
The C-type lectin receptor CLEC-2 acti-
vates platelets through Src and Syk ty-
rosine kinases, leading to tyrosine phos-
phorylation of downstream adapter
proteins and effector enzymes, including
phospholipase-C 2. Signaling is initi-
ated through phosphorylation of a single
conserved tyrosine located in a YxxL
sequence in the CLEC-2 cytosolic tail.
The signaling pathway used by CLEC-2
shares many similarities with that used
by receptors that have 1 or more copies
of an immunoreceptor tyrosine-based ac-
tivation motif, defined by the sequence
Yxx(L/I)x6-12Yxx(L/I), in their cytosolic tails
or associated receptor chains. Phosphor-
ylation of the conserved immunoreceptor
tyrosine-based activation motif tyrosines
promotes Syk binding and activation
through binding of the Syk tandem SH2
domains. In this report, we present evi-
dence using peptide pull-down studies,
surface plasmon resonance, quantitative
Western blotting, tryptophan fluores-
cence measurements, and competition
experiments that Syk activation by
CLEC-2 is mediated by the cross-linking
through the tandem SH2 domains with a
stoichiometry of 2:1. In support of this
model, cross-linking and electron micros-
copy demonstrate that CLEC-2 is present
as a dimer in resting platelets and con-
verted to larger complexes on activation.
This is a unique mode of activation of Syk
by a single YxxL-containing receptor.
(Blood. 2010;115(14):2947-2955)
Introduction
The C-type lectin receptor CLEC-2 is expressed on platelets and on
a subpopulation of other hematopoietic cells, including mouse
neutrophils and dendritic cells.1-3 CLEC-2 is a receptor for the
snake venom toxin rhodocytin4 and the transmembrane protein
podoplanin,5,6 which is expressed on the leading edge of tumor
cells and on kidney podocytes, lung type 1 alveolar cells, and
lymphatic endothelium. In addition, recent evidence suggests that
activated platelets express or release a ligand for CLEC-2 that
supports platelet aggregation at arteriolar rates of flow.7 Mice
pretreated with a specific antibody to CLEC-2 exhibit a selective
loss of the C-type lectin receptor and impaired platelet activation
on collagen at high shear in vitro or in vivo.7
Cross-linking of CLEC-2 by rhodocytin, podoplanin, or specific
antibodies elicits powerful platelet aggregation and secretion.4,6
CLEC-2 signals through Src- and Syk-dependent tyrosine kinases,
leading to phosphorylation of a series of adapter and effector
proteins that culminate in activation of phospholipase-C 2 (PLC2)
and platelet activation.4 This mechanism of platelet activation
resembles that used by the immunoglobulin collagen receptor,
glycoprotein VI (GPVI), which is constitutively associated with the
FcR chain at the platelet surface. Cross-linking of GPVI by
collagen or specific agonists, such as the snake venom toxin
convulxin or antibodies, leads to Src kinase-dependent phosphory-
lation of 2 conserved tyrosines in the FcR-chain immunoreceptor
tyrosine-based activation motif (ITAM).8,9 ITAMs are present in a
variety of hematopoietic receptors, including T- and B-cell antigen
receptors and the Fc receptors, FcRI, FcRIa, and FcRIIa, and
are defined by the sequence Yxx(L/I)6-12Yxx(L/I).10 Phosphoryla-
tion of the 2 conserved tyrosines on receptor activation provides
docking sites for the tandem SH2 domains in the only 2 known
members of the Syk family of tyrosine kinases, Syk and Zap-70,
leading to their activation and initiation of downstream signaling.
Although CLEC-2 signals through a pathway similar to that of
GPVI, it contains only a single YxxL sequence in its cytoplasmic
tail, which, by mutation of the tyrosine to a phenylalanine, has been
shown to be essential for activation of Syk.11 Two other C-type
lectin receptor family members, Dectin-1 and CLEC9A, have also
been shown to activate Syk through a single YxxL sequence
located in their cytosolic tails.12-14 Thus, it seems probable that
these 3 C-type lectin-like receptors may use a common mechanism
to regulate Syk via a single YxxL sequence.
Activation of Syk by CLEC-2 is ablated by point mutations in
either of the Syk SH2 domains that disrupt their ability to bind to
phosphotyrosines.11 This suggests a model in which activation of
Syk is mediated through cross-linking of 2 phosphorylated CLEC-2
receptors on the cell surface. This model is further supported by the
observation that a CLEC-2 specific F(ab)2 fragment but not a Fab
fragment mediates activation of mouse platelets.7 Further, the
related receptor, CLEC9A, is expressed as a covalent dimer on
dendritic cells, consistent with the cross-linking model.14 On the
other hand, these observations could be explained by the presence
of a second binding site on the cytosolic tail of CLEC-2, which
binds directly or via an intermediate protein to one of the Syk SH2
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domains. The present study was undertaken to investigate these
2 hypotheses to establish the mode of Syk activation by CLEC-2.
Methods
Reagents
Rhodocytin was purified from Calloselasma rhodostoma venom as previ-
ously described.15 A rabbit -Syk polyclonal antibody (pAb) was used as
previously reported.16 The goat -human CLEC-2 pAb was purchased from
R&D Systems. The -Myc monoclonal antibody was from Cell Signaling
Technology. The -mouse CLEC-2 pAb was kindly donated by Drs Katsue
Suzuki-Inoue and Yukio Ozaki (University of Yamanashi, Yamanashi,
Japan). The antibody to rhodocytin has been previously described.4 The
polyclonal -Src antibody was from Invitrogen. The polyclonal -FcRIIA
tail antibody was used as previously reported.17 Horseradish peroxidase
(HRP)–conjugated -rabbit and -goat secondary antibody and enhanced
chemiluminescence reagents were purchased from GE Healthcare. GST
fusion proteins corresponding to single or tandem SH2 domains of Syk
were prepared as described previously.18,19 Biotinylated peptides were
synthesized by Alta Bioscience and Severn Biotech. The Sulfo-EGS
cross-linking compound was from Pierce (Thermo Fisher Scientific). All
other reagents were purchased from Sigma-Aldrich or from previously
described sources.20
Platelet preparation
Venous blood from healthy drug-free volunteers was taken into 10%
sodium citrate. Washed platelets were obtained by centrifugation using
prostacyclin to prevent activation during the isolation procedure.21 Platelets
were resuspended in modified-Tyrode buffer (134mM NaCl, 0.34mM
Na2HPO4, 2.9mM KCl, 12mM NaHCO3, 20mM N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid, 5mM glucose, 1mM MgCl2; pH 7.3) as
previously described.21 Platelets were used at a cell density of 5  108/mL
unless stated.
Immunoprecipitation, pull-downs, and Western blotting
Washed platelets were pretreated with 9M Integrilin to inhibit platelet
activation and aggregation through integrin IIb3. Platelets were stimu-
lated with agonists at 37°C with stirring at 1200g in a Born lumi-
aggregometer. Reactions were terminated by addition of 2 times ice-cold
NP-40 lysis buffer. Platelet lysates were precleared, and detergent-insoluble
debris was discarded.21 An aliquot was dissolved with sodium dodecyl
sulfate (SDS) sample buffer for detection of total tyrosine phosphorylation.
Lysates were incubated with either the indicated antibodies and protein
G-Sepharose, or biotinylated CLEC-2 peptides and streptavidin-agarose.
Precipitated proteins or whole-cell lysates were separated by reducing
SDS-polyacrylamide gel electrophoresis (PAGE), electrotransferred, and
Western blotted. For in vitro pull-down studies, Syk GST-SH2 domain
proteins were incubated with a 50-fold excess of biotinylated CLEC-2
peptide, and the resulting complexes were precipitated with glutathione-
agarose. Samples were dot-blotted onto nitrocellulose membrane and
probed with HRP-conjugated streptavidin. Densitometry was performed to
quantitate the amount of peptide pulled out.
Platelet surface protein cross-linking
After platelet stimulation, Sulfo-EGS (0.15mM or 1.5mM final concentra-
tion) was added and allowed to incubate at room temperature for
30 minutes. The reaction was then quenched with the addition of Tris-HCl
(pH 7.5; 25mM final concentration), and allowed to incubate for a further
20 minutes at room temperature. The platelets were then lysed with the
addition of an equal volume of 2 times ice-cold NP-40 lysis buffer.
Constructs
Wild-type and Y7F CLEC-2 and wild-type FcR-chain cloned into pEF6
have been described previously.11,22 Further mutations were generated by a
2-step polymerase chain reaction method. The mutating primers CLEC-2
21-28-FWD (5-TAA-AAC-TCG-GAA-ACC-AGC-TCT-CAT-CTG-
GTG-GCG-TGT-GAT-GGC-TTT-GAT-TC-3), CLEC-2 21-28-REV (5-
GAA-TCA-AAG-CCA-TCA-CAC-GCC-ACC-AGA-TGA-GAG-CTG-
GTT-TCC-GAG-TTT-TA-3), CLEC-2 S21/27A-FWD (5-GAA-ACC-
AGC-TCT-CAT-CGC-CGT-TGG-CTC-TGC-ATC-CGC-CTC-CTG-GTG-
GC-3), CLEC-2 S21/27A-REV (5-GCC-ACC-AGG-AGG-CGG-ATG-
CAG-AGC-CAA-CGG-CGA-TGA-GAG-CTG-GTT-TC-3), CLEC-2 T9A-
FWD (5-CAT-GCA-GGA-TGA-AGA-TGG-ATA-CAT-CGC-CTT-AAA-
TAT-TAA-AAC-TCG-3), CLEC-2 T9A-REV (5-CGA-GTT-TTA-ATA-
TTT-AAG-GCG-ATG-TAT-CCA-TCT-TCA-TCC-TGC-ATG-3), FcR-
chain Y66F-FWD (5-CAG-ATG-GTG-TTT-TCA-CGG-GCC-TGA-G-
3), FcR-chain Y66F-REV (5-CTC-AGG-CCC-GTG-AAA-ACA-CCA-
TCT-G-3), FcR-chain Y77F-FWD (5-GGA-ACC-AGG-AGA-CTT-TCG-
AGA-CTC-TGA-AGC-3), and FcR-chain Y77-REV (5-GCT-TCA-GAG-
TCT-CGA-AAG-TCT-CCT-GGT-TCC-3) were used along with vector
specific primers 5147 and 4150. The nuclear factor of activated T cells
(NFAT) luciferase reporter contains 3 copies of the distal NFAT site from
the IL-2 promoter23 and was provided by Prof A. Weiss (University of
California San Francisco). The pEF6-lacZ expression construct was from
Invitrogen.
Cell culture and transfection
DT40 chicken B cells were grown in RPMI supplemented with 10% fetal
bovine serum, 1% chicken serum, 100 U/mL penicillin, 100 g/mL
streptomycin, 50M -mercaptoethanol, and 20mM GlutaMAX. Cells
were transfected in 400 L of cytomix by electroporation using a
GenePulser II (Bio-Rad) set at 350 V and 500 F.
Luciferase assay
Cells were transfected as described in “Cell culture and transfection” with
10 g of the indicated Myc-tagged or FLAG-tagged-CLEC-2 construct or 2
g/mL each of GPVI and the indicated Myc-tagged-FcR construct, 20 g
of the luciferase reporter construct, and 2 g of pEF6-lacZ to control for
transfection efficiency.11,22 Twenty hours after transfection, live cells were
counted by trypan blue exclusion and samples divided for luciferase assay,
-galactosidase assay, and flow cytometry. Luciferase assays were carried
out as described previously.24 Luciferase activity was measured with a
Centro LB 960 microplate luminometer (Berthold Technologies). Data
were normalized to -galactosidase activity and expressed as percentage of
the wild-type response. All luciferase data were averaged from triplicate
readings. -Galactosidase assays were performed with half of a million
cells using the Galacto-Light chemiluminescent reporter assay, according to
the manufacturer’s instructions (Applied Biosystems). -Galactosidase
activity was measured in triplicate using a microplate luminometer.
Immunogold labeling and electron microscopy
Washed mouse platelets were prepared as previously described.25 Nonstimu-
lated or rhodocytin (100nM for 2 minutes)–stimulated mouse platelets were
used for immunogold labeling and electron microscopy performed as
previously described.26 In nonstimulated platelets, CLEC-2 receptors were
labeled with CLEC-2 specific monoclonal IgG and 10-nm colloidal gold
particles coated with goat -mouse IgG. This approach could not be used to
label CLEC-2 in rhodocytin-stimulated platelets as the snake toxin either
masks the antibody epitope or induces a conformational change, which does
not allow the CLEC-2 specific antibody to bind. A rabbit polyclonal
antibody to rhodocytin and 10-nm colloidal gold particles coated with goat
anti–rabbit IgG was used instead.
Flow cytometry
Surface expression of Myc-tagged-CLEC-2 and the Myc-tagged-FcR
mutants was measured by flow cytometry. Cells (5  105) were stained in a
25-L volume for 20 minutes on ice with 10 g/mL -Myc antibody. Cells
were then washed and incubated for 20 minutes on ice with 15 g/mL
fluorescein isothiocyanate–conjugated -mouse IgG secondary antibody.
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Stained cells were analyzed using a FACSCalibur (BD Biosciences). Data
were collected and analyzed using CellQuest software (BD Biosciences).
Surface plasmon resonance
Surface plasmon resonance experiments were performed using a Biacore
T100 machine (Biacore, GE Healthcare). Biotin tagged CLEC-2 and FcR
peptides were attached to carboxymethylated dextran-coated CM5 research
grade sensor chips (Biacore) after attachment of streptavidin to the chip
surface using amine coupling. All experiments were performed at 25°C in
10mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, pH 7.4,
150mM NaCl, 1mM MgCl2, 0.005% Surfactant P-20. A range of concentra-
tions (0-80M) of N-SH2, C-SH2, and tandem SH2 domains were injected
over all peptide surfaces to determine equilibrium dissociation constants
(KD). Specific binding was identified by subtraction of signal from an
appropriate reference flow cell. Equilibrium dissociation constants (KD
values) were derived from global fitting to the predicted function using the
Levenberg-Marquardt algorithm as implemented in the program Origin
(OriginLab).
Tryptophan fluorescence titration
Fluorescence measurements were performed in a PTI spectrofluorimeter
(Photon Technology International). Both Syk SH2 domains and CLEC-2
peptides were extensively dialyzed into experimental buffer (50mM
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 150mM NaCl,
150mM glycine, 1mM ethylenediaminetetraacetic acid, and 5mM -mercap-
toethanol; pH 7.5) before experimentation. Protein and peptide concentra-
tions were determined by spectrophotometry using a ND-1000 spectropho-
tometer (Nanodrop; Thermo Scientific). The Syk SH2 domains (3 mL of
250nM) were loaded into a quartz cuvette and placed into the cell turret
with constant stirring. The CLEC-2 peptide (2mM) was titrated in and
allowed to mix for 2 minutes before scanning. An excitation wavelength of
295 nm was used, and emission spectra were collected over the range of
300 to 420 nm in 2.5-nm steps. Slit widths of 0.75 mm were used for both
excitation and emission. The peak fluorescence of 340 nm was monitored to
calculate the equilibrium dissociation constant, KD.
Statistical analysis
NFAT-luciferase data are expressed as geometric mean plus or minus SE.
Statistical analysis was carried out using the unpaired Student t test.
Significance was taken P less than .05.
Results
Structure-function relationship of the CLEC-2 cytoplasmic tail
and Syk tandem SH2 domains
Sequence alignment of the CLEC-2 cytosolic tail both between
species and with the 2 other family members, Dectin-1 and
CLEC9A, was performed to highlight conserved regions that might
provide a second binding site for one of the SH2 domains of Syk or
for an intermediate adapter protein. Sequence alignment of 9 spe-
cies of CLEC-2 using ClustalW (www.ebi.ac.uk/clustalw) high-
lighted conservation of the N-terminal MQDEDGYxTL sequence,
a threonine at position 	2 in the YxxL motif and of 2 serine
residues located at positions 21 and 27 in human CLEC-2 (Figure
1A). Several positively charged amino acids and a tryptophan-
arginine (WR) sequence at the juxtamembrane position were also
conserved. Sequence alignment of 9 species of Dectin-1 also
highlighted conservation of the DEDGYxxL sequence and of 2
serine residues (Figure 1B) but not the other amino acids that were
conserved in CLEC-2 apart from the membrane WR sequence.
Intriguingly, a conserved threonine residue was found at the 	1
position in the Dectin-1 YxxL motif. The same relationship did not
hold for CLEC9A, with the conserved DEDG sequence being
replaced by the similarly charged EEEI sequence and just one of
the serines and the threonine at position Y	1 being conserved. The
presence of the conserved serine and threonine residues is of
interest given their potential for phosphorylation. Further, the
presence of a threonine group at position Y 	 1 or Y 	 2 is of also
of interest given previous observations in mast cells and mouse
platelets that phosphorylation of a conserved threonine at position
Y 	 1 in 1 of the 2 YxxL sequences of the FcR-chain by a novel
isoform of protein kinase C (
 or ) is required for maximal binding
and activation of Syk.27-29
Based on these alignments, experiments were designed to
investigate the role of the YxxL, and the conserved serine and
threonine residues in the cytoplasmic tail of CLEC-2 through a
combination of peptide pull-down studies using human CLEC-2
Figure 1. Sequence alignment of CLEC-2 family proteins. (A)
Ten species of CLEC-2 were aligned using ClustalW web-based
software, highlighting conservation of the DEDGYxTL motif and
serines at positions 21 and 27. (B) Nine species of Dectin-1 were
aligned, highlighting conservation of the DEDGYTxL motif and
serines at positions 32 and 40. (C) The intracellular tails of
CLEC-2, Dectin-1, and CLEC9Awere aligned, highlighting conser-
vation of the YxxL motif and partial conservation of a serine-rich
region.
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cytosolic peptides and human mutant CLEC-2 transfected into
chicken DT40 B cells. The latter is a hematopoietic cell line that we
have used extensively to investigate signaling by both CLEC-2 and
GPVI using a sensitive NFAT reporter assay.22,30
In confirmation of our previous finding,11 the snake toxin
rhodocytin stimulates powerful activation of NFAT activity in
CLEC-2 but not in mock-transfected DT40 cells, with the response
ablated after mutation of the conserved tyrosine at position 7 to
phenylalanine as shown later in Figure 3. In line with this, a
phosphorylated peptide based on the first 13 amino acids of the
CLEC-2 tail, which includes the conserved MQDEDGYxxL
sequence, was able to effectively precipitate Syk from a platelet
lysate, whereas the corresponding nonphosphorylated 13-amino
acid peptide was ineffective (Figure 2Ai). Significantly, there was
no increase in the amount of precipitated Syk when a tyrosine-
phosphorylated peptide based on the full 31-amino acid cytoplas-
mic tail of CLEC-2 was used, although again the nonphosphory-
lated peptide was ineffective (Figure 2Ai). This demonstrates that a
single phosphorylated YxxL sequence is sufficient to mediate
binding to Syk and that a similar level of binding is seen with the
13 and the full-length 31-amino acid peptides based on the CLEC-2
tail in the pull-down assay. It is unclear, however, whether the
interaction with Syk in this design is mediated through binding of
2 separate phosphorylated peptides to the tandem SH2 domains in
the kinase, bearing in mind that multiple phosphorylated peptides
are attached to the beads. These observations therefore do not rule
out a possible direct or indirect interaction between the Syk tandem
SH2 domains and a second site in the CLEC-2 cytosolic tail, which
may support the association of Syk with a CLEC-2 monomer in an
intact cell.
The contribution of the 2 conserved serine residues in the
CLEC-2 tail to the interaction with Syk and to intracellular
signaling was investigated using the same approach as for the YxxL
motif. Mutation of the 2 serine residues to alanine, or deletion of
the serine-rich region (21-28) had no significant effect on surface
expression or the ability of the mutant CLEC-2 receptor to activate
NFAT in the DT40 cell line relative to the wild-type receptor
(Figure 2Bi; supplemental Figure 1, available on the Blood
website; see the Supplemental Materials link at the top of the online
article). Further, a 31-amino acid tyrosine-phosphorylated peptide
containing alanine residues rather than serine groups at positions
21 and 27 associated with a similar level of Syk as the tyrosine-
phosphorylated wild-type peptide (Figure 2Aii). These results
demonstrate that neither of the conserved serine residues plays a
significant role in supporting Syk association or in signaling to
PLC2 and NFAT activation.
Using the same approach, we were also unable to find evidence
for a functional role for the threonine at position 9 in signaling by
CLEC-2. Transfection of DT40 cells with the T9A mutant of
CLEC-2 had no significant effect on surface expression or on NFAT
activation induced by rhodocytin relative to the wild-type receptor
(Figure 2Bii; supplemental Figure 2). Further, a tyrosine-
phosphorylated 31 amino acid peptide containing a phosphorylated
threonine residue precipitated similar levels of Syk as the wild-type
phosphorylated peptide (Figure 2Aiii).
These results confirm a critical role for the phosphorylated
YxxL sequence in both the interaction with Syk and in mediating
NFAT signaling by CLEC-2 in transfected DT40 cells but also
demonstrate that the 2 conserved serines at positions 21 and 27 and
the partially conserved threonine at position 9 are dispensable for
these events. The functional role of these 3 residues therefore
remains to be determined. The present results indirectly favor a
model in which Syk cross-links 2 molecules of CLEC-2 via its
2 SH2 domains, both of which are known to be essential for
CLEC-2 signaling.11
Inhibitory action of Y7F CLEC-2 on signaling by wild-type
CLEC-2
To further investigate whether cross-linking of 2 CLEC-2 receptors
is required for activation of Syk, we coexpressed wild-type
CLEC-2 with various levels of the Y7F mutant of CLEC-2, which
is unable to bind to Syk (Figure 2Ai) and does not support NFAT
activation (Figure 3).11 The rationale for this experiment is that the
Y7F mutant should have an inhibitory effect if the cross-linking
model is correct by forming an “inactive heterodimer” with the WT
receptor. On the other hand, it should have no effect if Syk is
activated by a monomeric CLEC-2 receptor as the Y7F mutant is
unable to support binding to Syk and activation.
Surface expression of wild-type CLEC-2 was unaffected by
expression of the Y7F mutant in DT40 cells (supplemental Figure
3), whereas NFAT activation was dramatically inhibited when the
mutant receptor was expressed at a similar or greater level than the
wild-type receptor (Figure 3). Reducing the level of expression of
the Y7F mutant caused a corresponding reduction in the inhibitory
effect. In contrast, the weak constitutive (agonist-independent)
Figure 2. YxxL is essential for Syk association and
signaling through CLEC-2. (A) Washed platelets
(5  108/mL) were lysed with 2 times NP40 lysis buffer,
precleared, and interacting proteins precipitated with the
addition of 10 g of the relevant biotinylated CLEC-2
peptide. Precipitated proteins were separated by SDS-
PAGE and Western blotted for the presence of Syk.
(B) DT40 cells were transfected with 10 g/mL of the
stated CLEC-2 construct and an NFAT-luciferase re-
porter plasmid. Transfected cells were stimulated with
50nM rhodocytin for 6 hours at 37°C, and then the
luciferase activity was measured as an index of signaling.
Results were normalized for transfection efficiency and
plotted as a percentage of the wild-type response. Error
bars represent the geometric mean  SE of 3 to 6
separate experiments.
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signal induced by expression of CLEC-2, which we have previ-
ously described,22 was not inhibited in the presence of the Y7F
mutant, suggesting that it may be mediated by a CLEC-2 monomer
(Figure 3). These data provide evidence that ligand-activated
CLEC-2 signals as a dimer/oligomer and that expression of the
Y7F inactive mutant has a “dominant negative” effect by inducing
a portion of the native receptors into a mixed (wild-type and Y7F)
dimeric or higher-order structure that is unable to signal.
CLEC-2 is present in higher-order structures on the platelet
surface
The results shown in Figures 2 and 3 provide evidence that
dimerization of CLEC-2 is essential for Syk activation. To investi-
gate whether CLEC-2 is present as a dimer or higher-order
structure on platelets, we used Sulfo-EGS, a cross-linking reagent
that cross-links proteins that fall within a distance of 1.6 nm (16Å)
of each other. Dimerization and oligomerization of CLEC-2 were
investigated by immunoprecipitation and Western blotting.
In nonstimulated or rhodocytin-stimulated platelets, CLEC-2
migrates on reducing SDS-PAGE gel electrophoresis as a character-
istic doublet because of differential glycosylation (Figure 4A lanes
1 and 4).4 The molecular weights of the 2 differentially glycosy-
lated forms of CLEC-2, 30 and 40 kDa, are consistent with both
forms being a monomer, which is further supported by the fact that
they are reduced to a single band of just less than 30 kDa on
deglycosylation.4 After addition of a low or a high concentration of
cross-linker, the presence of higher molecular weight bands of
CLEC-2 can be seen together with a corresponding reduction in
intensity of the 30- and 40-kDa bands. In nonstimulated platelets, a
new broad band is observed at between 60 and 80 kDa, which
corresponds approximately to a doubling of the molecular weight
of monomeric CLEC-2 (Figure 4A, lanes 2 and 3). With the higher
concentration of cross-linker, there is also the suggestion of the
presence of higher-order structures in nonstimulated platelets,
which corresponds to a further reduction in the monomeric form
and to a reduction in the dimeric form relative to the lower
concentration of Sulfo-EGS. In the presence of rhodocytin, Sulfo-
EGS induces the formation of both the predicted CLEC-2 dimer
and higher-order structures, most notably at the upper concentra-
tion where there is almost no detectable monomeric CLEC-2
(Figure 4A lanes 5 and 6).
The corresponding changes in the levels of monomeric, dimeric,
and oligomeric forms of CLEC-2 are consistent with the intercon-
version of one form to another, although there is also the suggestion
of loss of protein with the higher concentration of cross-linker, a
conclusion supported by densitometric analysis (not shown). The
loss of protein may reflect the formation of higher-order structures
that are resistant to solubilization. The broad nature and smearing
of bands seen in these studies are probably the consequence of
oligomerization of the differentially glycosylated forms of CLEC-2
as well as possible cross-linking to other proteins, although
interestingly, Western blotting studies failed to detect the presence
of rhodocytin in the higher-order structures, suggesting that
cross-linking to the toxin had not occurred (not shown).
A similar overall pattern of change in CLEC-2 dimerization/
oligomerization was seen in whole-cell lysates prepared from basal
(not shown) and rhodocytin-activated platelets, as demonstrated by
Western blotting for CLEC-2 (Figure 4B). In marked contrast, there
was no apparent dimerization/oligomerization of the low-affinity
immune receptor, FcRIIA, or the membrane-associated protein
Src in the presence of the intermediate and high concentration of
Sulfo-EGS in basal (not shown) or rhodocytin-activated platelets
(Figure 4B) as shown by the similar levels of the monomeric forms
of both proteins as revealed by Western blotting (Figure 4B). These
results demonstrate that the oligomerization of CLEC-2 is not
simply the result of a nonspecific effect of cross-linking of platelet
surface proteins.
We also investigated possible dimerization/oligomerization of
CLEC-2 by immunogold labeling and electron microscopy on
Figure 3. The Y7F CLEC-2 mutant inhibits signaling by the wild-type receptor.
DT40 cells were transfected with 10 g/mL of wild-type CLEC-2 and/or various
amounts of Y7F CLEC-2 and an NFAT-luciferase reporter gene. Transfected cells
were stimulated with 50nM rhodocytin for 6 hours at 37°C, after which time the
amount of luciferase activity was measured as a readout of signaling. Results were
normalized for transfection efficiency and plotted as a percentage of the wild-type
response. Error bars represent the geometric mean  SE of 3 to 8 separate
experiments.
Figure 4. CLEC-2 oligomers are present on the plate-
let surface. Washed platelets (5  108/mL) under basal
or rhodocytin-stimulated (100nM) conditions had their
surface proteins cross-linked with the addition of 0.15mM
or 1.5mM Sulfo-EGS cross-linking reagent, with a linker
length of 1.6 nm (16 Å). The cross-linking reaction was
subsequently blocked, and then the platelets were lysed
with 2 NP40 lysis buffer. (A) Lysates were precleared
with protein G-Sepharose and then immunoprecipitated
with -CLEC-2 antibody and protein G-Sepharose. Pre-
cipitated proteins were separated by reducing SDS-
PAGE and Western blotted for CLEC-2. (B) Lysates were
separated by reducing SDS-PAGE and Western blotted
for CLEC-2, FcRIIA, and Src. The results are represen-
tative of 3 experiments.
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nonstimulated and rhodocytin-stimulated mouse platelets using a
specific antibody to the C-type lectin receptor (Figure 5). Under
nonstimulated conditions, approximately 35% and 50% of gold
particles were found alone or in pairs, respectively, with the latter
separated by a mean distance of 14 nm. These results further
suggest that, under basal conditions, CLEC-2 is present as a
monomer and dimer on the platelet surface. Furthermore, after
rhodocytin stimulation, more than 55% of gold particles are present
in clusters of 4 or more gold particles demonstrating the formation
of oligomers.
These 2 distinct approaches demonstrate that a significant
proportion of CLEC-2 is present as dimer on the surface of a
nonstimulated platelet and that the receptor is converted to higher
oligomeric structures on activation. Furthermore, the CLEC-2
dimer is not the consequence of disulphide cross-linking as the
C-type lectin receptor runs solely as a monomer under both
reducing (Figure 4) and nonreducing conditions (supplemental
Figure 4).
Surface plasmon resonance and tryptophan fluorescence
measurements
The result in Figure 4 further supports a model in which the tandem
SH2 domains in Syk bind to the phosphorylated YxxL sequence in
separate CLEC-2 receptors, which are preformed into dimers. This
is consistent with our previous report that point mutants that disrupt
binding of the individual SH2 domains to phosphotyrosine abro-
gate signaling by CLEC-2.11 One prediction of this model is that
both of the SH2 domains in Syk must be able to bind to the
phosphorylated YxxL peptide. This was investigated using surface
plasmon resonance to measure the equilibrium dissociation con-
stants (KD) of binding of the N-terminal, C-terminal, and tandem
SH2 domains of Syk. To achieve this, each protein was flowed over
different surfaces coated with the nonphosphorylated or phosphor-
ylated 13-amino acid N-terminal CLEC-2 peptide. No detectable
binding was observed for any of the SH2 domain-containing
proteins when flowed over the nonphosphorylated CLEC-2 pep-
tide, confirming the requirement for tyrosine phosphorylation of
the YxxL. When flowed over the tyrosine-phosphorylated peptide,
a KD of 10.5M was calculated for the Syk N-SH2 domain and
2.4M for the Syk C-SH2 domain, demonstrating that both SH2
domains are able to bind to the phosphorylated CLEC-2 cytoplas-
mic tail. Moreover, when the tSH2 domain protein was flowed over
tyrosine-phosphorylated CLEC-2 peptide, a KD of 256nM was
calculated, thereby demonstrating cooperativity between the 2 SH2
domains. This is consistent with each SH2 domain binding to
separate molecules of the phosphorylated CLEC-2 peptides on the
surface of the chip. As a comparison, the individual and tandem
Syk SH2 domains were also flowed over a dually phosphorylated
peptide based on the human FcR-chain ITAM. A similar cooperat-
ivity was observed when the tandem SH2 domains were flowed
over the peptide with a calculated KD of 20nM compared with the
individual KD values of the N- and C-terminal SH2 domains of 19.7
and 1.7M, respectively (Figure 6A). These data demonstrate that
the Syk tandem SH2 domain protein binds with higher affinity than
the single Syk SH2 domains to a surface containing multiple copies
of a phosphorylated YxxL-containing peptide. This has important
implications for the binding of Syk to a dually phosphorylated
ITAM protein or to the phosphorylated CLEC-2 tail when pre-
sented as a dimer. Consistent with these data, quantitative Western
blotting was used to show that twice the amount of a CLEC-2
peptide was able to associate with the tandem-SH2 domains of Syk
compared with the single SH2 domains alone, confirming a 2:1
stoichiometry of CLEC-2 to Syk (Figure 6B).
Tryptophan fluorescence titration was used to derive a second
estimate of the affinity of the tandem Syk SH2 domains for the
phosphorylated CLEC-2 peptide.19,31 This technique is based on the
Figure 5. Electron microscopy and immunogold staining of
CLEC-2 on resting and rhodocytin-stimulated mouse plate-
lets. (Ai,Bi) Electron micrograph showing -CLEC2 immunostain-
ing. The majority of CLEC-2 immunogold labeling can be found
within a pair (solid arrows) or alone (open arrowheads) under
basal conditions (A) or as larger clusters after rhodocytin stimula-
tion and rhodocytin immunogold labeling (B). Scale bar repre-
sents 50 nm. (Aii,Bii) Quantification of the CLEC-2 immunogold
labeling distribution under basal (A) or rhodocytin-stimulated (B)
conditions. The distribution of CLEC-2 immunogold labeling is
depicted as a histogram. Data represent the mean plus or minus
SD (n  5). (Aiii) Quantification of the distance between CLEC-2
immunogold-labeled pairs. The intercenter distance between the
gold particles within pairs was measured using ImageJ (n  100)
and presented as a box-and-whisker plot. Solid horizontal line
shows the median for the data, the top of the box the 25th
percentile, the bottom the 75th percentile, and the additional lines
the range of the data.
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principle that binding to the peptide causes a change in fluores-
cence of 1 or more tryptophan groups in the tandem Syk SH2
domain. The N-terminal 13-amino acid CLEC-2 peptide was used
for these studies as this supports a similar level of binding of Syk to
that of the 31-amino acid phosphorylated peptide and does not
contain a tryptophan residue. Addition of the peptide resulted in a
saturatable decrease in peak tryptophan fluorescence of the tandem
Syk SH2 domain at 340 nm, indicative of ligand binding (Figure 7).
The resulting dissociation constant (KD) of 5.7M for the Syk-
tandem SH2/CLEC-2 interaction was of a similar order as the KD
derived by surface plasmon resonance of CLEC-2 peptide binding
to either the N- or C-terminal SH2 domain of Syk. In contrast, the
fluorescence data recorded a 20-fold weaker binding to the tSH2
than was observed by surface plasmon resonance. This discrepancy
may reflect the influence of avidity in the binding between the Syk
tandem SH2 domains and a surface-immobilized peptide, whereas
the tryptophan fluorescence measurements were made in solution.
In contrast, we were unable to detect binding of the CLEC-2
peptide to the single C-terminal SH2 domain of Syk over the same
concentration range. The equivalent experiment is not valid for the
N-terminal SH2 domain as this does not contain a tryptophan
residue. This increased affinity of the tSH2 domain for a CLEC-2
peptide compared with the single C-terminal SH2 domain mirrors
the result seen using surface plasmon resonance. It should be noted,
however, that there is also 1 tryptophan residue in the linker region
that is present only in the tSH2 domain. It is therefore possible that
ligand binding is causing only the linker region tryptophan to
change its fluorescence and this too would explain the lack of
binding to the C-terminal SH2 domain.
GPVI requires both FcR-chain YxxL sequences to signal
The results in Figures 2 to 7 support a dimerization model of
CLEC-2 signaling. This raises the question as to whether ITAM
receptors, which contain a tandem YxxL sequence, are able to
activate Syk through intermolecular binding between adjacent
phosphorylated YxxL sequences or whether intramolecular binding
to the doubly phosphorylated YxxLs of a single ITAM is essential
for activation. This question was addressed through the generation
of single point mutations (Y-F) of the conserved ITAM tyrosines in
the FcR-chain, which associates with GPVI. An N-terminal
Myc-tagged version of the FcR-chain, which supports a similar
level of signaling to that of the wild-type protein,22 was used in
these studies to enable measurement of the level of surface
expression. As shown in Figure 8, mutation of the C-terminal
ITAM tyrosine abolished NFAT activation by collagen in DT40
cells transfected with GPVI and the mutant FcR-chain, whereas
mutation of the N-terminal ITAM tyrosine suppressed the response
by more than 95%, despite similar expression levels of both GPVI
and FcR-chain as measured by flow cytometry (supplemental
Figure 5). Thus, these results demonstrate that both ITAM tyrosines
are required for robust signaling by the GPVI-FcR -chain
complex and that the FcR-chain is unable to function efficiently
with phosphorylation of only a single YxxL.
Discussion
The results presented in the previous section support a model in
which CLEC-2 regulates Syk through dimerization with each of the
Figure 6. Surface plasmon resonance measurements and quantitative Western blotting of the CLEC-2-Syk SH2 interaction. (A) Biotinylated CLEC-2 and FcR chain
peptides were bound to streptavidin-coated biosensor chip surfaces. The N-SH2, C-SH2, or the tandem SH2 domains of Syk were purified and flowed over the chip at a range
of concentrations. Nonlinear regression was used to analyze the data and calculate KD values. The results are representative of 3 experiments. (B) GST-tagged Syk SH2
domain proteins were incubated with a 50-fold excess of biotinylated phospho-CLEC-2 peptide and precipitated with glutathione-agarose beads. The precipitated proteins
were dot-blotted, and the amount of associated CLEC-2 was measured using HRP-streptavidin and densitometric analysis. The result is representative of 4 experiments.
Figure 7. Tryptophan fluorescence titration measurements of the CLEC-2-Syk
SH2 interaction. The purified tandem SH2 domains of Syk were placed into a quartz
cuvette in a Photon Technology International spectrofluorimeter. After excitation at
295 nm, emission at 340 nm was plotted during titration of a CLEC-2 peptide.
Nonlinear regression was used to analyze the data and calculate KD values. The
graph is representative of 3 experiments.
Figure 8. GPVI signaling requires both ITAM tyrosines. DT40 cells were
transfected with 2 g/mL stated FcR-chain construct, 2 g/mL GPVI, along with an
NFAT-luciferase reporter gene. Transfected cells were then stimulated with 10 g/mL
collagen for 6 hours at 37°C, after which time the amount of luciferase activity was
measured as a readout of signaling. Results were normalized for transfection
efficiency and plotted as a percentage of the wild-type response. Error bars represent
the geometric mean SE of 3 separate experiments.
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2 Syk SH2 domains binding to a phosphorylated YxxL sequence in
the individual cytosolic tails of CLEC-2, which itself is present as a
dimer on the platelet surface. The evidence in support of this model
is as follows: (1) it has previously been reported that both SH2
domains of Syk are essential for activation by CLEC-211; (2) the
CLEC-2 cytosolic tail contains a single YxxL sequence that, when
phosphorylated, is essential for activation of NFAT; (3) a signifi-
cant proportion of CLEC-2 is present as a dimer in nonstimulated
platelets and converted to higher-order structures on stimulation;
(4) coexpression of FxxL mutant CLEC-2 inhibits signaling by the
wild-type receptor; (5) there is no evidence for a second (direct or
indirect) binding site for Syk in the CLEC-2 cytoplasmic tail; (6)
surface plasmon resonance has shown that both SH2 domains of
Syk have micromolar affinity for the tyrosine-phosphorylated
CLEC-2 and that they interact in a cooperative manner to facilitate
binding; and (7) quantitative Western blotting confirms a stoichiom-
etry of 2:1 for the interaction between CLEC-2 and Syk. The other
C-type lectin receptors, which have been shown to regulate Syk
through a single YxxL sequence, Dectin-1, and CLEC9A, may also
function as dimers. An alignment of the cytoplasmic tails of all 3
receptors emphasizes their overall similarity in organization but
fails to identify a conserved or recognized sequence that probably
confers binding, either directly or indirectly, to the second SH2
domain of Syk. Further, CLEC9A is expressed as a covalently
linked dimer, adding weight to the proposed dimerization model.14
These data therefore suggest that the minimum signaling unit for
CLEC-2 and the 2 related C-type lectin receptors is a phosphory-
lated dimer, enabling recruitment of a single molecule of Syk. An
alternative model in which Syk cross-links 2 CLEC-2 dimers is
also possible.
The cross-linking experiments in stimulated platelets also
indicate the presence of oligomeric forms of CLEC-2, and it is
possible that these contribute to the proposed model for activation
of Syk by creating a critical density of phosphorylated YxxLs.
Alternatively, the apparent formation of CLEC-2 oligomers may be
the result of binding to rhodocytin, which is a tetramer and so could
therefore cross-link multiple receptors,32 although the presence of
the snake toxin itself in these higher-order structures was not
detected. It is also possible that the higher molecular structures
could represent binding to other membrane proteins, although no
specific binding partners of CLEC-2 have been reported.
Oligomerization of CLEC-2 on the platelet surface is also
supported by electron microscopy, which clearly demonstrates
couplets of CLEC-2 on the surface of resting platelets with a
separation of only 14 nm. In the crystal structure of monomeric
CLEC-2, the shortest axis of the monomer is approximately 20 nm
and the longest axis is approximately 40 nm.33 Therefore, the
epitope that is bound by the antibody used in these studies must lie
on a region of the surface of each CLEC-2 monomer that is near the
equivalent region on the paired monomer. This is probably near the
dimer interface. Although the crystal structure of CLEC-2 fails to
predict a dimerization motif, C-type lectin-like molecules can form
dimers with a reasonably large interface without a precise dimeriza-
tion motif. In the related C-type lectin-like molecule NKG2D, for
example, large patches of surface on the monomers interact to
produce the dimer, and the interface includes 19 hydrogen bonds
and 72 van der Waals contacts.34 The surface buried within the
dimer interface of NKG2D accounts for approximately 15% of the
total monomer surface. The size of the CLEC-2 dimer interface is
unclear, but the interface is sufficiently strong to hold the 2 mono-
mers together in the absence of disulfide bond formation. It will be
particularly interesting to establish whether or not the distance
between the labeled antibodies is altered in the presence of ligand,
which could in principle introduce a conformational change in the
dimer configuration. If this occurs, then the interface itself may
undergo a significant change on ligand binding, which might be of
significance with respect to CLEC-2 phosphorylation and intracel-
lular signaling.
The dimerization model represents a unique mode of regulation
of Syk and contrasts with that used by ITAM receptors, which
require phosphorylation of the 2 conserved tyrosines in the ITAM
for optimal signaling. Given the dimerization model, it is of interest
to consider why the FcR-chain does not function in this way as
shown by the dramatic inhibition of NFAT activation after mutation
of the individual FcR-chain YxxL sequences. One possible
explanation is that the FcR-chain, which is a covalent dimer, is
expressed in a conformation that does not favor cross-linking of
YxxL groups on separate chains, possibly to minimize constitutive
signaling in the absence of agonist binding. On the other hand, the
presence of 2 YxxL groups on the same chain facilitates binding to
proteins with tandem SH2 domains without a need for receptor
dimerization/oligomerization. This is illustrated by comparison of
the KDs derived for binding of single and tandem SH2 domains of
Syk to immobilized tyrosine-phosphorylated peptides in the
surface plasmon resonance experiments described in Figures 6
and 7. Dual YxxL groups that form an ITAM are found in
separate exons (http://www.ensembl.org), suggesting that ITAM-
like receptors may have preceded ITAM receptors. The greater
number of ITAM receptors over ITAM-like receptors may
reflect an evolutionary advantage in having 2 YxxL groups on
the same protein, although this may also reflect the fact that the
majority of ITAM receptors are composed of multiple chains
and therefore unable to undergo dimerization/oligomerization.
Indeed, it is noteworthy that the low-affinity immune receptor,
FcRIIA, which contains 2 YxxL groups in a classic ITAM
sequence, does not appear to be present as a dimer in resting
platelets as shown in the cross-linking studies.
In conclusion, the present observations support a novel dimer-
ization model of activation of Syk by the C-type lectin receptor
CLEC-2 in which the tyrosine kinase cross-links 2 CLEC-2
receptors through binding of its tandem SH2 domains to the
conserved YxxL motif in each receptor. Confirmation of this model
in an intact cell will require the application of specialist fluorescence-
based imaging techniques, such as Fo¨rster resonance energy
transfer. Such studies are ongoing in the laboratory.
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